201 views
Stock image by zinkevych

iX Biopharma upsizes placement to raise $6.7m

It will fund expanses from its US expansion and purchase of new equipment amongst others.

iX Biopharma Ltd has upsized its proposed placement to 67 million new shares, increasing its aggregate gross proceeds to $6.7m from the initial $5m target, the company said in a filing. 

The new shares represent about 7% of its enlarged share capital of 955.84 million.

The proceeds are expected to fund expenses in connection with the group's expansion into the US, purchase of equipment, general working capital and fees, and expenses incurred in the proposed placement of $300,000, and debt repayment. 

Institutional investors, including Lion Global Investors Limited (on behalf of its clients) and Ginko-AGT Global Growth Fund, subscribed to the placement. The shares were issued under the general mandate approved at the company’s 2025 annual general meeting.

iX Biopharma will seek approval for the listing and quotation of the new shares on the Singapore Exchange’s Catalist board through its sponsor, UOB Kay Hian Private Limited. The company confirmed that none of its directors or substantial shareholders participated in the placement.
 

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.